Pages that link to "Q60685688"
Jump to navigation
Jump to search
The following pages link to Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation (Q60685688):
Displaying 50 items.
- Follicular lymphoma: 2012 update on diagnosis and management (Q22252956) (← links)
- Idiotype vaccination for Non-Hodgkin lymphoma (Q24186272) (← links)
- High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults (Q24203878) (← links)
- Idiotype vaccination for Non-Hodgkin lymphoma (Q24235281) (← links)
- Follicular lymphoma: 2011 update on diagnosis and management (Q26851450) (← links)
- Functional genomics lead to new therapies in follicular lymphoma (Q26852415) (← links)
- Systemic Front Line Therapy of Follicular Lymphoma: When, to Whom and How (Q28073262) (← links)
- Principles of maintenance therapy (Q28243883) (← links)
- Fc Gamma Receptor 3A and 2A Polymorphisms Do Not Predict Response to Rituximab in Follicular Lymphoma (Q30278460) (← links)
- Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. (Q30370665) (← links)
- Recombinant antibodies for the diagnosis and treatment of cancer (Q31166188) (← links)
- Radioimmunotherapy of small-volume disease of metastatic colorectal cancer (Q33341317) (← links)
- Rituximab monotherapy is highly effective in splenic marginal zone lymphoma (Q33375317) (← links)
- Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial (Q33418964) (← links)
- A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma. (Q33419840) (← links)
- Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape (Q33621041) (← links)
- Rituximab in indolent lymphomas (Q33764062) (← links)
- Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial (Q33830194) (← links)
- A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma (Q34007430) (← links)
- Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia (Q34186569) (← links)
- The biology of human lymphoid malignancies revealed by gene expression profiling. (Q34313320) (← links)
- Rituximab maintenance in relapsed or refractory follicular non-Hodgkin's lymphoma: the evidence of its therapeutic value (Q34449805) (← links)
- Rituximab: mechanisms and applications (Q34462378) (← links)
- Autologous stem cell transplantation in follicular non-Hodgkin's lymphoma (Q34526368) (← links)
- In vivo purging and relapse prevention following ASCT. (Q34526378) (← links)
- Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma (Q34619308) (← links)
- Anti-CD20-based therapy of B cell lymphoma: state of the art. (Q34926739) (← links)
- Is there a role for reduced-intensity haematopoietic stem cell transplantation for indolent non-Hodgkin's lymphoma? (Q35022123) (← links)
- Monoclonal antibody therapy for B-cell lymphoma (Q35038955) (← links)
- The war on cancer: a report from the front lines (Q35103643) (← links)
- Transformed lymphoma: an Achilles' heel of non-Hodgkin's lymphoma (Q35106138) (← links)
- FcgammaR polymorphisms: Implications for function, disease susceptibility and immunotherapy. (Q35106872) (← links)
- Antibody therapy of non-Hodgkin's B-cell lymphoma (Q35109771) (← links)
- Germinal center reentries of BCL2-overexpressing B cells drive follicular lymphoma progression (Q35145329) (← links)
- Monoclonal antibody therapy for lymphoma (Q35158950) (← links)
- New strategies in radioimmunotherapy for lymphoma (Q35190687) (← links)
- Treatment of low-grade B-cell lymphoma with the monoclonal antibody rituximab (Q35206348) (← links)
- Adding cytokines to monoclonal antibody therapy: does the concurrent administration of interleukin-12 add to the efficacy of rituximab in B-cell non-hodgkin lymphoma? (Q35210415) (← links)
- Immunotherapy with anti-CD20 compounds (Q35213332) (← links)
- Minimal residual disease (MRD) in follicular lymphoma in the era of immunotherapy with rituximab (Q35213336) (← links)
- Overview of Antibody Therapy in B-Cell Non-Hodgkin's Lymphoma (Q35558322) (← links)
- Clinical use of rituximab in haematological malignancies (Q35561014) (← links)
- Non-Hodgkin lymphoma: an update (Q35789262) (← links)
- Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis (Q35794369) (← links)
- B cell non-Hodgkin's lymphoma: rituximab safety experience (Q36165319) (← links)
- Follicular lymphoma: management options in the era of targeted therapy (Q36168712) (← links)
- Has the time to come leave the "watch-and-wait" strategy in newly diagnosed asymptomatic follicular lymphoma patients? (Q36372975) (← links)
- Efficacy and safety of rituximab combined with chemotherapy in the treatment of diffuse large B-cell lymphoma: a meta-analysis (Q36411549) (← links)
- Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies (Q36426877) (← links)
- Rituximab maintenance therapy in indolent NHL: a clinical review (Q36496164) (← links)